全文获取类型
收费全文 | 23131篇 |
免费 | 1528篇 |
国内免费 | 432篇 |
专业分类
耳鼻咽喉 | 125篇 |
儿科学 | 399篇 |
妇产科学 | 309篇 |
基础医学 | 2940篇 |
口腔科学 | 279篇 |
临床医学 | 2984篇 |
内科学 | 5322篇 |
皮肤病学 | 350篇 |
神经病学 | 1026篇 |
特种医学 | 482篇 |
外国民族医学 | 1篇 |
外科学 | 1823篇 |
综合类 | 1504篇 |
现状与发展 | 2篇 |
一般理论 | 47篇 |
预防医学 | 3919篇 |
眼科学 | 374篇 |
药学 | 1411篇 |
25篇 | |
中国医学 | 547篇 |
肿瘤学 | 1222篇 |
出版年
2024年 | 89篇 |
2023年 | 2343篇 |
2022年 | 5163篇 |
2021年 | 6853篇 |
2020年 | 4562篇 |
2019年 | 257篇 |
2018年 | 239篇 |
2017年 | 193篇 |
2016年 | 219篇 |
2015年 | 240篇 |
2014年 | 389篇 |
2013年 | 405篇 |
2012年 | 310篇 |
2011年 | 390篇 |
2010年 | 341篇 |
2009年 | 317篇 |
2008年 | 304篇 |
2007年 | 319篇 |
2006年 | 307篇 |
2005年 | 241篇 |
2004年 | 253篇 |
2003年 | 221篇 |
2002年 | 145篇 |
2001年 | 129篇 |
2000年 | 107篇 |
1999年 | 87篇 |
1998年 | 82篇 |
1997年 | 60篇 |
1996年 | 74篇 |
1995年 | 43篇 |
1994年 | 29篇 |
1993年 | 39篇 |
1992年 | 27篇 |
1991年 | 29篇 |
1990年 | 22篇 |
1989年 | 13篇 |
1988年 | 11篇 |
1987年 | 8篇 |
1985年 | 36篇 |
1984年 | 37篇 |
1983年 | 23篇 |
1982年 | 23篇 |
1981年 | 23篇 |
1980年 | 16篇 |
1979年 | 13篇 |
1977年 | 10篇 |
1976年 | 5篇 |
1975年 | 10篇 |
1974年 | 6篇 |
1973年 | 18篇 |
排序方式: 共有10000条查询结果,搜索用时 250 毫秒
1.
《Vaccine》2022,40(52):7515-7519
The recent wave of COVID-19 cases has led to the potential need for booster doses. We surveyed 6,294 people and found that 87.6% reported willingness to take a booster dose, with vaccine efficacy rate being the most common reason cited to accept booster dose. Differences in acceptance rates were noted among those working in non-health related sectors, different ethnic groups as well as those who had taken viral vector vaccines. 相似文献
2.
《Journal of infection and chemotherapy》2022,28(12):1639-1644
IntroductionSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) first broke out in Wuhan in December 2019, and has since caused a global pandemic. The efficacy of several drugs has been evaluated, and it is now evident that tocilizumab has a beneficial effect, especially combined with corticosteroids, in patients with Coronavirus Disease 2019 (COVID-19). However, the optimal timing of tocilizumab administration has not yet been established. The goal of the present study was to determine the optimal timing of tocilizumab administration after starting corticosteroid therapy in patients with COVID-19.MethodsWe retrospectively analyzed the clinical characteristics of patients who were hospitalized for COVID-19 and treated with tocilizumab and corticosteroids in our hospital. The patients were divided into concurrent and sequential groups. The concurrent group received tocilizumab ≤24 h after corticosteroids, and the sequential group received tocilizumab >24 h after corticosteroid administration.ResultsThe baseline clinical characteristics of tocilizumab administration were similar between the two groups. White blood cell counts were significantly lower and C-reactive protein levels were significantly higher in the concurrent group than the sequential group. In the concurrent group, tocilizumab administration led to a significant decrease in maximum body temperature. In addition, there were significantly more oxygen-free days in the concurrent group than in the sequential group. However, survival rate was not significantly different between the concurrent and the sequential groups.ConclusionsIn the combination therapy with tocilizumab and corticosteroids, early administration of tocilizumab after starting corticosteroid treatment is effective when treating COVID-19. 相似文献
3.
Defining con-founders that affect the reliability of diagnostic tests for coronavirus disease 2019 is vital to breaking the chain of infection. The elderly population is a higher risk group for the emerging virus. However, gender seems to exert a critical role in modifying the infection risk among women owing to hormonal changes. The menopause transition is an exceptional period for older women where the protective and immunomodulatory effects of the estrogen hormone are lost. Accordingly, attention should be given to postmenopausal women since they will have an increased risk compared to their pre-menopausal peers. 相似文献
4.
《Journal of shoulder and elbow surgery / American Shoulder and Elbow Surgeons ... [et al.]》2022,31(1):201-208
- Download : Download high-res image (239KB)
- Download : Download full-size image
5.
6.
《Vaccine》2022,40(27):3721-3726
We initiated a randomized, placebo-controlled, phase 1/2 trial to evaluate the safety and immunogenicity of the S-268019-b recombinant protein vaccine, scheduled as 2 intramuscular injections given 21 days apart, in 60 randomized healthy Japanese adults. We evaluated 2 regimens of the S-910823 antigen (5 μg [n = 24] and 10 μg [n = 24]) with an oil-in-water emulsion formulation and compared against placebo (n = 12). Reactogenicity was mild in most participants. No serious adverse events were noted. For both regimens, vaccination resulted in robust IgG and neutralizing antibody production at days 36 and 50 and predominant T-helper 1-mediated immune reaction, as evident through antigen-specific polyfunctional CD4+ T-cell responses with IFN-γ, IL-2, and IL-4 production on spike protein peptides stimulation. Based on the interim analysis, the S-268019-b vaccine is safe, produces neutralizing antibodies titer comparable with that in convalescent serum from COVID-19-recovered patients. However, further evaluation of the vaccine in a large clinical trial is warranted. 相似文献
7.
BackgroundTraditional Chinese medicine (TCM) has been proven to played a great important role on the treatment of COVID-19. As one of the drugs recommended in Chinese guidelines, Lianhua Qingwen Granules or Capsules (LQ) are widely used.This systematic review and meta-analysis amis to evaluate the clinical efficacy of LQ on the treatment of COVID-19.MethodsSeven databases (PubMed, EMBASE, CENTRAL, CNKI, VIP, CBM and Wanfang) were searched to include all appropriate clinical trials that explore the efficacy of LQ on the treatment of COVID-19.ResultA total of 3 trials including 245 COVID-19 patients were eventually enrolled.Compared with the control group,the LQ group showed great significant difference on reducing the rate of clinical change to severe or critical condition[RR = 0.38, 95 %CI (0.17,0.85), P < 0.05]and the fever time (SMD =-0.57,95 %CI (-0.96,-0.17), P<0.05),as well as the significant improvement on the disappearance rate of the clinical symptoms: fever [RR = 1.36,95 %CI (1.14,1.61), P < 0.05],cough[RR = 1.99,95 %CI (1.39,2.86), P < 0.05],fatigue[RR = 1.52,95 %CI (1.15,2.01), P < 0.05] and anhelation [RR = 4.18,95 %CI (1.99,8.81), P < 0.05], but no significance on expectoration[RR = 2.46,95 %CI (0.81,7.51), P < 0.05].ConclusionThe clinical application of LQ on the treatment of COVID-19 has significant efficacy in improving clinical symptoms and reducing the rate of clinical change to severe or critical condition. Nevertheless, due to the limited quantity and quality of the included studies, more and higher quality trials with more observational indicators are expected to be published. 相似文献
8.
Hannah C. Nordhues Anjali Bhagra Natya N. Stroud Jennifer A. Vencill Carol L. Kuhle 《Mayo Clinic proceedings. Mayo Clinic》2021,96(7):1907-1920
The coronavirus disease 2019 (COVID-19) pandemic has rapidly created widespread impacts on global health and the economy. Data suggest that women are less susceptible to severe illness. However, sex-disaggregated data are incomplete, leaving room for misinterpretation, and focusing only on biologic sex underestimates the gendered impact of the pandemic on women. This narrative review summarizes what is known about gender disparities during the COVID-19 pandemic and the economic, domestic, and health burdens along with overlapping vulnerabilities related to the pandemic. In addition, this review outlines recommended strategies that advocacy groups, community leaders, and policymakers should implement to mitigate the widening gender disparities related to COVID-19. 相似文献
9.
10.